| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
in00004356213 |
| 005 |
20210728140413.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
151130s2015 enk o 000 0 eng d |
| 019 |
|
|
|a 918860954
|
| 020 |
|
|
|a 1782620931
|
| 020 |
|
|
|a 1849739080
|
| 020 |
|
|
|a 9781782620938
|
| 020 |
|
|
|a 9781849739085
|
| 024 |
3 |
|
|a 9781849739085
|
| 035 |
|
|
|a (OCoLC)990728751
|z (OCoLC)918860954
|
| 035 |
|
|
|a (OCoLC)ocn990728751
|
| 035 |
|
|
|a 6431769
|
| 037 |
|
|
|a 3503:3385
|b Royal Society of Chemistry
|n http://www.rsc.org/spr
|
| 040 |
|
|
|a LIP
|b eng
|e pn
|c LIP
|d OCLCO
|d UKRSC
|d UIU
|d OCLCF
|d COO
|d IDEBK
|d YDXCP
|d EBLCP
|d NOC
|d OCLCQ
|d OCL
|d OCLCA
|d OCLCQ
|d AU@
|d OCLCO
|d OCLCA
|d LVT
|d OCLCA
|d LEAUB
|d OCLCO
|d UAB
|d OCLCO
|d UKAHL
|d OL$
|d OCLCQ
|d OCLCA
|d OCLCQ
|d OCLCA
|d OCLCQ
|d SXB
|d EYM
|d UtOrBLW
|
| 049 |
|
|
|a TXAM
|
| 050 |
|
4 |
|a RM301.25.F73 2015
|
| 060 |
0 |
0 |
|a 2015 K-133
|
| 060 |
1 |
0 |
|a QV 745
|
| 066 |
|
|
|c (S
|
| 082 |
0 |
4 |
|a 615.19
|
| 100 |
1 |
|
|a Jhoti, Harren.
|0 http://id.loc.gov/authorities/names/nb2007004753
|
| 245 |
1 |
0 |
|a Fragment-Based Drug Discovery.
|
| 246 |
3 |
|
|a Drug Discovery
|
| 246 |
3 |
|
|a RSC Drug Discovery
|
| 264 |
|
1 |
|a Cambridge :
|b Royal Society of Chemistry,
|c 2015.
|
| 300 |
|
|
|a 1 online resource (314 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a RSC Drug Discovery
|
| 500 |
|
|
|a 3.2.3 Other Applications of STD and WaterLOGSY Experiments.
|
| 500 |
|
|
|a Electronic resource.
|
| 505 |
0 |
|
|6 880-01
|a Cover ; Fragment-Based Drug Discovery; Foreword ; Preface ; Contents; Personal Essay: Fragments in the Blogosphere; 1 Introduction; 2 A Living Review; 3 Warning Signs and Guideposts; 4 A Mirror for the Community; 5 Beyond Practical Fragments: Fragments in the Broader Social Media; Acknowledgements; References; Personal Essay: Adventures and Experiences in Fragment-Based Drug Discovery; 1 In the Beginning; 2 We are all Brought up to be Fragment Practitioners; 3 Setting up Fragment Screening at RiboTargets/Vernalis; 3.1 Targeting Hsp90.
|
| 505 |
8 |
|
|a 1.5.1 Assigning Function1.5.2 Assessing Ligandability; 1.5.3 Speeding Up Chemical Validation; 1.6 Targeting Protein-Protein Interactions and Beyond; 1.7 Targeting Oligonucleotides; 1.8 Concluding Remarks; References; Chapter 2 -- Getting the Most Value from Your Screens: Advances in Hardware, Software, and Methodologies to Enhance Surface Plasmon Resonance Based Fragment Screening and Hit-to-Lead Support; 2.1 Introduction; 2.2 SPR Technology as Applied to FBS; 2.3 The Basic Screening Cascade; 2.4 Advances in Data Reduction and Active Selection in Primary Screening.
|
| 505 |
8 |
|
|a 2.4.1 Robust Drift Correction by Local Estimation2.4.2 Method #1 for Hit Detection: Box Plots; 2.4.3 Method #2 for Hit Detection: Normal-Exponential Convolution Model; 2.4.4 Implementation and Automation in R; 2.5 High-Throughput Competition Experiments for Binding Site and MOA Studies; 2.5.1 Configuring SPR-Competition Assays; 2.5.2 A Quantitative Specificity Metric for Selecting Competitive Compounds; 2.6 Hardware Improvements; 2.6.1 SensiQ Pioneer Hardware and Novel Types of Injections; 2.6.2 Screening by Gradient Injections: Hardware and Software Integration; 2.7 Conclusions; References.
|
| 505 |
8 |
|
|a Chapter 3 -- Applications of NMR in Fragment-Based Drug Design3.1 Introduction; 3.2 Ligand-Observed Experiments; 3.2.1 STD Experiments; 3.2.1.1 Principle and Experimental Conditions; 3.2.1.2 Recent Pulse Sequence Development; 3.2.1.3 STD as a Tool for Fragment Screening and Fragment Ranking; 3.2.1.4 STD as a Tool for Binding-Mode Assessment; 3.2.2 WaterLOGSY Experiments; 3.2.2.1 Principle and Experimental Conditions; 3.2.2.2 Recent Pulse Sequence Development; 3.2.2.3 WaterLOGSY as a Tool For Fragment Screening and Fragment Ranking; 3.2.2.4 WaterLOGSY as a Tool for Binding-Mode Assessment.
|
| 520 |
|
|
|a This book will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in drug discovery techniques.
|
| 546 |
|
|
|a English.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Drug development.
|0 http://id.loc.gov/authorities/subjects/sh97007921
|
| 650 |
|
0 |
|a Ligands (Biochemistry)
|0 http://id.loc.gov/authorities/subjects/sh89002279
|
| 650 |
|
2 |
|a Biological Science Disciplines.
|0 https://id.nlm.nih.gov/mesh/D001690
|
| 650 |
|
2 |
|a Chemical Actions and Uses.
|0 https://id.nlm.nih.gov/mesh/D020164
|
| 650 |
|
2 |
|a Chemistry, Pharmaceutical.
|0 https://id.nlm.nih.gov/mesh/D002626
|
| 650 |
|
2 |
|a Chemistry.
|0 https://id.nlm.nih.gov/mesh/D002621
|
| 650 |
|
2 |
|a Drug Discovery.
|0 https://id.nlm.nih.gov/mesh/D055808
|
| 650 |
|
2 |
|a Investigative Techniques.
|0 https://id.nlm.nih.gov/mesh/D008919
|
| 650 |
|
2 |
|a Laboratory Chemicals.
|0 https://id.nlm.nih.gov/mesh/D019995
|
| 650 |
|
2 |
|a Ligands.
|0 https://id.nlm.nih.gov/mesh/D008024
|
| 650 |
|
2 |
|a Natural Science Disciplines.
|0 https://id.nlm.nih.gov/mesh/D010811
|
| 650 |
|
2 |
|a Pharmacology.
|0 https://id.nlm.nih.gov/mesh/D010600
|
| 650 |
|
2 |
|a Specialty Uses of Chemicals.
|0 https://id.nlm.nih.gov/mesh/D020313
|
| 650 |
|
4 |
|a Health & Biological Sciences.
|
| 650 |
|
4 |
|a Pharmacy, Therapeutics, & Pharmacology.
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Health & Biological Sciences.
|2 hilcc
|
| 650 |
|
7 |
|a Ligands (Biochemistry)
|2 fast
|0 (OCoLC)fst00998471
|
| 650 |
|
7 |
|a Pharmacy, Therapeutics, & Pharmacology.
|2 hilcc
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a De Esch, Iwan.
|
| 700 |
1 |
|
|a Drysdale, Martin.
|
| 700 |
1 |
|
|a Erlanson, Daniel A.
|0 http://id.loc.gov/authorities/names/nb2006018735
|
| 700 |
1 |
|
|a Giannetti, Tony.
|
| 700 |
1 |
|
|a Hann, Michael.
|0 http://id.loc.gov/authorities/names/n92063862
|
| 700 |
1 |
|
|a Hughes, Terry.
|0 http://id.loc.gov/authorities/names/n50029416
|
| 700 |
1 |
|
|a Krimm, Isabelle.
|
| 700 |
1 |
|
|a Kutchukian, Peter.
|
| 700 |
1 |
|
|a Spry, Christina.
|
| 830 |
|
0 |
|a RSC drug discovery series.
|0 http://id.loc.gov/authorities/names/no2010092643
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://dx.doi.org/10.1039/9781782620938
|z Connect to the full text of this electronic book
|t 0
|
| 880 |
0 |
|
|6 505-01/(S
|a 4 The Future of Fragment-Based Methods -- The Future is Now4.1 Challenging Targets; 4.1.1 β-Site Amyloid Precursor Protein Cleaving Enzyme 1; 4.1.2 G Protein-Coupled Receptors; 4.1.3 Protein-Protein Interactions; 4.1.4 Allosteric Site Inhibitors; 4.2 Progress in the Absence of Crystal Structures; 4.3 New, Novel Different Fragments; 5 Fragment Discovery Outside Industry; 6 Summary; References; Chapter 1 -- Different Flavours of Fragments; 1.1 Fragment-Based Drug Discovery; 1.2 Different Types of Fragments; 1.3 How We Identify Fragments; 1.4 Selectivity; 1.5 Applications of Fragment-Based Methods.
|
| 955 |
|
|
|a RSC eBooks
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|s e497e674-86bb-3092-89d9-e5eb854e4ef2
|i a1f9d77f-672e-3512-a87f-53b34bacb342
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|d Available Online
|t 0
|e RM301.25.F73 2015
|h Library of Congress classification
|
| 998 |
f |
f |
|a RM301.25.F73 2015
|t 0
|l Available Online
|